 |
|
Comparative Clinical Effectiveness and Toxicity of Vancomycin, Ristocetin, and Kanamycin
BURTON A. WAISBREN, M.S., M.D.;
LEONARD KLEINERMAN, M.D.;
JOSEPH SKEMP, M.D.;
GLENN BRATCHER, B.S.
Arch Intern Med. 1960;106(2):179-193.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
Patients with severe staphylococcal infections that have not responded to the usual antimicrobial therapy are common in present-day hospital practice. It is hoped that the data to be presented regarding the relative efficacy and toxicity of ristocetin, vancomycin, and kanamycin will help the clinician to make a decision about further antimicrobial therapy for these patients. It was possible to alternate the use of ristocetin, vancomycin, and kanamycin in a group of seriously ill patients because the three drugs were discovered within such a short time of each other that no one of them had an opportunity to be established as "the drug of choice" in severe staphylococcic infections.1-3 Each of these three antibiotics acted as a control for the others in the study, and this circumvented the necessity of extrapolating opinions regarding their effectiveness in severe infections from actual experience with milder, non-life-threatening infections.
Materials and Methods
Drugs.
—Ristocetin
. . . [Full Text PDF of this Article]
Author Affiliations
Milwaukee
From the infectious disease control unit of the Department of Medicine of the Milwaukee County General Hospital and the Marquette University School of Medicine.
Footnotes
Submitted for publication Dec. 5, 1959.
Presented in part at the Antibiotics Symposium in Washington, D.C., Nov. 5, 1959.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
